• New HEPATITIS E VirClia®
    Highly convenient solution for daily HEV testing

    Amplification Controls

    Guarantee the quality of your molecular assays

  • VirClia® Monotest
    Bring flexibility to your lab
    with the largest infectious serology panel

  • Respiratory virus testing
    The complete solution for respiratory virus testing;
    screening and identification

Featured product



XXIII SEIMC Congress Fungal Symposium

At the symposium "Biomarkers of Fungal Infection" we will discuss issues related to invasive fungal infection, experts' recommendations, and the use of biomarkers to identify this serious pathology. May 23 at 6:30 p.m. in Rome room at IFEMA, Madrid.

More information

Development and production of diagnostic reagents for human infectious diseases

Vircell is a biotechnology company specialized in the development and production of ready to use reagents for human infectious diseases. We are present in laboratories of more than 80 countries worldwide on five continents. Vircell offers more than 400 references for the detection of bacteria, viruses, parasites and fungi by means of different techniques: ELISA, chemiluminescence, direct and indirect immunofluorescence, immunocapture agglutination, cell culture and Molecular Biology (oligochromatography and PCR controls).


Vircell is present in laboratories of more than 80 countries worldwide. International Sales constitute one of the major sources of income for the company thanks to the constant work of our commercial team, who has a deep knowledge of the international market. If you need further information on the distribution of our products in your country, do not hesitate to contact us.

More information
22 April 2019 Biomarkers of Fungal Infection - Expert Opinion The symposium "Biomarkers of Fungal Infection - Expert Opinion" will take place at the next ...
05 May 2019 ASM Clinical Virology Symposium Vircell will be attending the 2019 ASM Clinical Virology Symposium, which will take place in ...


Sign up for our newsletter and you will receive our latest news in your e-mail